Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics, based on research at Harvard Medical School and Brigham & Women’s Hospital.

Tilos Therapeutics, a US-based biopharmaceutical company advancing research from Harvard University and Brigham & Women’s Hospital, yesterday agreed to an acquisition worth up to $773m by pharmaceutical group Merck & Co. Merck will, through an unnamed subsidiary, purchase all outstanding shares in Tilos and make an upfront payment, with additional contingent milestone payments. Details of…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.